

Katherine Bach Kalin is Corporate Vice President of Strategy at Celgene, a global, biopharmaceutical company that discovers, develops and commercializes innovative therapies for cancer and immune-inflammatory diseases. In this role, Katherine leads the development and articulation of the company's long-range plan and conducts a broad array of strategic and financial assessments of new business opportunities. Prior to joining Celgene in 2012, Katherine spent nine years in operational leadership roles at Johnson and Johnson (J&J) in Global Marketing, US Sales and Marketing, New Business Development, and Business Insights across three J&J business units. Katherine joined J&J from McKinsey and Company, where she was a partner in the Global Pharmaceuticals and Medical Products Practice, with responsibility for negotiating and leading a diverse range of global consulting assignments from 1990-2002. Katherine's deep industry insight and multi-disciplined expertise have enabled her to thrive in a variety of roles in global corporate and professional services environments. She has a BA from Durham University in the UK, and an MBA from Harvard Business School. Katherine is a dual citizen of the US and the UK, and has significant international work experience, in Asia, Europe and North America. She speaks fluent French and conversational Spanish.

